Clinical Trial Update: Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating zoledronic acid in children aged 1 to 17 with severe osteogenesis imperfecta has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Osteogenesis Imperfecta | Phase 2 | Status: COMPLETED